Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. The Company's product candidates utilize Edge’s proprietary, programmable, biodegradable polymer-based development platform.

Edge Therapeutics novel delivery mechanism seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standard of care systemic delivery. Its initial product candidates target rare, acute, life-threatening neurological conditions for which we believe the approved existing therapies, if any, are inadequate.

StateClosed
TypeSubsidiary
Parent CompanyPDS Biotechnology
HQBerkeley Heights, US
Founded2009
Websiteedgetherapeutics.com
Edge Therapeutics was founded in 2009 and is headquartered in Berkeley Heights, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Edge Therapeutics

Brian Leuthner

Brian Leuthner

President and CEO
Herbert J. Faleck

Herbert J. Faleck

Chief Medical Officer
Albert N. Marchio

Albert N. Marchio

Chief Accounting and Administrative Officer
W. Bradford Middlekauff

W. Bradford Middlekauff

Senior Vice President and General Counsel
Andrew Saik

Andrew Saik

CFO
Alyssa J. S. Wyant

Alyssa J. S. Wyant

Senior Vice President, Regulatory Affairs
Show more

Edge Therapeutics Office Locations

Edge Therapeutics has an office in Berkeley Heights
Berkeley Heights, US (HQ)
300 Connell Dr #4000
Show all (1)

Edge Therapeutics Financials and Metrics

Summary Metrics

In total, Edge Therapeutics had raised $101.5 m. Edge Therapeutics is a subsidiary of PDS Biotechnology

Edge Therapeutics Revenue

Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

8.7m14.7m17.7m14.3m11.0m

R&D expense

17.8m24.8m34.3m16.1m6.1m

Operating expense total

26.5m39.5m52.0m40.3m17.1m

EBIT

(26.5m)(39.5m)(52.0m)(43.1m)(21.0m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

2.0m3.7m3.3m3.6m4.2m4.2m4.0m4.7m3.3m3.3m3.9m2.4m3.1m

R&D expense

6.5m5.3m6.0m6.7m7.6m9.0m6.9m12.7m2.5m317.7k1.0m1.9m1.8m

Operating expense total

8.5m9.0m9.3m10.3m11.8m13.1m10.9m17.4m12.5m4.5m4.9m4.3m4.9m

EBIT

(8.5m)(9.0m)(9.3m)(10.3m)(11.8m)(13.1m)(10.9m)(20.1m)(12.5m)(4.5m)(4.9m)(4.3m)(5.8m)
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(28.1m)(38.8m)(50.9m)(40.9m)(7.0m)

Depreciation and Amortization

53.1k100.1k182.9k174.3k98.4k

Accounts Payable

(71.8k)1.4m898.1k(4.0m)(2.0m)

Cash From Operating Activities

(21.8m)(32.2m)(40.7m)(33.2m)(18.1m)
Show all financial metrics

Edge Therapeutics Online and Social Media Presence

Embed Graph

Edge Therapeutics News and Updates

Edge Therapeutics Announces Full Year 2018 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018.

EDGE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Edge Therapeutics, Inc. - EDGE

NEW ORLEANS, Nov. 29, 2018 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Edge Therapeutics, Inc. ("EDGE") (NasdaqGS: EDGE) with PDS Biotechnology Corporation in a...

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer-

Edge Therapeutics Reports Third Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018.

Edge Therapeutics Reports Second Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended June 30, 2018.

Edge Therapeutics Frequently Asked Questions

  • When was Edge Therapeutics founded?

    Edge Therapeutics was founded in 2009.

  • Who are Edge Therapeutics key executives?

    Edge Therapeutics's key executives are Brian Leuthner, Herbert J. Faleck and Albert N. Marchio.

  • Who are Edge Therapeutics competitors?

    Competitors of Edge Therapeutics include AbbVie, MyoKardia and Athersys.

  • Where is Edge Therapeutics headquarters?

    Edge Therapeutics headquarters is located at 300 Connell Dr #4000, Berkeley Heights.

  • Where are Edge Therapeutics offices?

    Edge Therapeutics has an office in Berkeley Heights.

  • How many offices does Edge Therapeutics have?

    Edge Therapeutics has 1 office.